Abstract
This chapter provides a survey of key nonclinical safety assays. For each study type, we discuss the typical study designs employed, including a summary of the type of endpoints collected. We then provide an overview of common statistical approaches in each setting. There are some general themes that are common across the study types (e.g., trend testing). At the same time, the different study types may have features that require special consideration (e.g., cross-over designs for safety pharmacology studies, intra-litter correlation in reproductive toxicology studies). While some of the design aspects of these studies are to some extent “fixed” by precedent across the industry, we do address sample size and power considerations, as this information can be valuable to understanding how statistical results can contribute to the overall interpretation of these studies. Finally, for any discussion of statistical approaches, there are likely to be multiple reasonable approaches. We’ve attempted to cover some of the more common approaches in detail, but we recognize that our treatment is not exhaustive. Where possible, we have provided references for further reading.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bailey SA (1998) Subchronic toxicity studies. In: Chow S-C, Liu J-P (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 135–195
Bailey S (2006) Design and analysis issues in juvenile animal toxicity studies for pharmaceutical development: a statistician’s perspective. Poster presented at the teratology society meetings, Tucson, AZ, 26 June 2006. Abstract: Birth Defects Research 76, p 383
Bailey S (2008) Relationships between litter size and resorptions, dead, and live fetuses: implications for statistical analysis and data interpretation. Poster presented at the teratology society meetings, Monterey, CA, 30 June 2008. Abstract: Birth Defects Research 82, p 352
Barlow RE, Bartholomew DJ, Bremner JM, Brunk HD (1972) Statistical inference under order restrictions. Wiley, New York
Bradley DR, Russell RL (1998) Some cautions regarding statistical power in split-plot designs. Behav Res Methods Insturm Comput 30(3):462–477
Bretz F, Hothorn LA (2003) Statistical analysis of monotone or non-monotone dose–response data from in vitro toxicological assays. Altern Lab Anim 31:81–96
Catalano PJ, Ryan LM (1992) Bivariate latent variable models for clustered discrete and continuous outcomes. J Am Stat Assoc 87:651–658
Catalano PJ, Scharfstein DO, Ryan LM, Kimmel CA, Kimmel GL (1993) Statistical model for fetal death, fetal weight, and malformation in developmental toxicity studies. Teratology 47: 281–290
Chen J (1998) Analysis of reproductive and developmental studies. In: Chow S, Liu J (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 309–355
Chen J (2000) Reproductive studies. In: Chow S (ed) Encyclopedia of biopharmaceutical statistics. Marcel Dekker, New York, pp 445–453
Chen J, Gaylor D (1992) Correlations of developmental end points observed after 2,4,5-trichlorophenoxyacetic acid exposure in mice. Teratology 45:241–246
Chen JJ, Kodell RL, Howe RB, Gaylor DW (1991) Analysis of trinomial responses from reproductive and developmental toxicity experiments. Biometrics 47:1049–1058
Ciminera J (1985) Some issues in the design, evaluation, and interpretation of tumorigenicity studies in animals. In: Proceedings of the symposium on long-term animal carcinogenicity studies: a statistical perspective. American Statistical Association, Washington, DC, pp 26–35
Clinical and Laboratory Standards Institute (2000) How to define and determine reference intervals in the clinical laboratory: approved guideline, vol 2. CLSI, CLSI document C28-A2, Wayne
Crump K (1984) A new method for determining allowable daily intakes. Fundam Appl Toxicol 4:854–871
Dorato MA, Engelhardt JA (2005) The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul Toxcol Pharmacol 42:265–274
Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50:1096–1121
EP Evaluator (2005) Release 7 (EE7). Computer software for evaluating clinical laboratory methods. David G. Rhoads Associates, Kennett Square
Filipsson AF, Sand S, Nilsson J, Victorin K (2003) The benchmark dose method—review of available models, and recommendations for application in health risk assessment. Crit Rev Toxicol 33(5):505–542
Healey GF (1999) The F1 approximate parametric test for monotonicity. Internal Technical Information Document ST9725, Department of Statistics, Huntingdon Life Sciences, Huntingdon
International Conference on Harmonization (2001) S7A – Safety pharmacology studies for human pharmaceuticals. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074959.pdf. Accessed 1 Sept 2014
International Conference on Harmonization (2005) S5(R2) – detection of toxicity to reproduction for medicinal products & toxicity to male fertility. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S5_R2/Step4/S5_R2__Guideline.pdf. Accessed 1 Oct 2014
International Conference on Harmonization (2010) M3(R2) – nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 30 June 2014
Jonckheere AR (1954) A distribution-free k-sample test against ordered alternatives. Biometrika 41:133–145
Lachin J (2011) Power and sample size evaluation for the Cochran–Mantel–Haenszel mean score (Wilcoxon rank sum) test and the Cochran–Armitage test for trend. Stat Med 30:3057–3066
Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22
McBride WG (1961) Thalidomide and congenital abnormalities. Lancet 2:1138
McCarthy JC (1967) Effects of litter size and maternal weight on foetal and placental weight in mice. J Reprod Fertil 14:507–510
Palmer AK (1974) Statistical sampling and choice of sampling units. Teratology 10:301–302
Rochon J (1991) Sample size calculation for two-group repeated-measures experiments. Biometrics 47:1383–1398
Ryan L (1992) Quantitative risk assessment for developmental toxicity. Biometrics 48:163–174
Selwyn MR (1988) Preclinical safety development. In: Peace KE (ed) Biopharmaceutical statistics for drug development. Marcel Dekker, New York, pp 231–271
Shirley E (1977) A nonparametric equivalent of Williams’ test for contrasting existing dose levels of a treatment. Biometrics 33:386–389
Senn S (2007) Statistical issues in drug development. Wiley, Chichester, pp 99–100
Sivarajah A1, Collins S, Sutton MR, Regan N, West H, Holbrook M, Edmunds N (2010) Cardiovascular safety assessments in the conscious telemetered dog: utilisation of super-intervals to enhance statistical power. J Pharmacol Toxicol Methods 62(1):12–19
Sparrow S, Robinson S, Bolan S, Bruce C, Danks A, Everett D, Fulcher S, Hill RE, Palmer H, Scott EW, Chapman KL (2011) Opportunities to minimize animal use in pharmaceutical regulatory general toxicology: a cross-company review. Regul Toxicol Pharmacol 61:222–229
Staples RE, Haseman JK (1974) Selection of appropriate experimental units in teratology. Teratology 9:259–260
Tukey JW, Ciminera JL, Heyse JF (1985) Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 41(1):295–301
U.S. Food and Drug Administration (2006) Guidance for industry – nonclinical safety evaluation of pediatric drug products. U.S. Food and Drug Administration, Rockville
Weaver J, Brunden M (1998a) Design of developmental and reproductive toxicity studies. In: Chow S, Liu J (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 291–308
Weaver J, Brunden M (1998b) The design of long term carcinogenicity studies. In: Chow S, Liu J (eds) Design and analysis of animal studies in pharmaceutical development. Marcel Dekker, New York, pp 227–258
Williams DA (1971) A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 27:103–117
Williams DA (1972) The comparison of several dose levels with a zero dose control. Biometrics 28:519–531
Williams DA (1975) The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. Biometrics 31:949–952
Zeger SL, Liang KY (1986) Longitudinal data for discrete and continuous outcomes. Biometrics 42:121–130
Zoetis T, Walls I (eds) (2003) Principles and practices for direct dosing of pre-weaning mammals in toxicity testing and research. A report of the ILSI risk science institute expert working group. ILSI, Washington DC
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Bailey, S.A., Li, D., Potter, D.M. (2016). General Toxicology, Safety Pharmacology, Reproductive Toxicology, and Juvenile Toxicology Studies. In: Zhang, L. (eds) Nonclinical Statistics for Pharmaceutical and Biotechnology Industries. Statistics for Biology and Health. Springer, Cham. https://doi.org/10.1007/978-3-319-23558-5_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-23558-5_10
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23557-8
Online ISBN: 978-3-319-23558-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)